Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 15/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23907468 | 0.95 | NT5E (0.45) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907390 | 0.91 | ADORA1 (0.45) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907422 | 0.91 | ADORA1 (0.43) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907536 | 0.90 | NT5E (0.47) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907537 | 0.90 | NT5E (0.45) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907401 | 0.90 | NT5E (0.44) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907534 | 0.90 | NT5E (0.46) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907387 | 0.90 | CTSL (0.47) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL23907469 | 0.89 | NT5E (0.45) | NT5EADORA1ADORA3ADORA2ATAS1R3 | |
| SCHEMBL21839615 | 0.89 | NT5E (0.56) | NT5EADORA1ADORA3ADORA2ATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | NT5E 5/4885ADORA1 16/4885ADORA3 9/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885ADORA1 34/4885ADORA3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.